Microbiome-Brain Axis: FMT for Depression

The gut-brain axis moved from theoretical biology to clinical application in 2025. A Phase III randomized controlled trial published in The Lancet Psychiatry found fecal microbiota transplantation (FMT) from healthy donors reduced depression severity scores by 39% in treatment-resistant depression patients — a population where existing antidepressants have failed. The follow-up 12-month data showed the effect persisted in 71% of responders, suggesting durable remission rather than temporary relief. Mechanistically, the transplanted microbiome altered tryptophan metabolism, increasing gut production of serotonin precursors and reducing systemic inflammatory markers that correlate with depression severity. Concurrent research identified specific bacterial strains responsible for the antidepressant effect, opening a path toward targeted probiotic formulations. An estimated 100 million people worldwide have treatment-resistant depression; this finding represents the first new mechanism of action in psychiatry in over 30 years.